(214)has shown that both the pharmacological inhibition of LIF and the genetic deletion of LIF markedly delay tumor progression and augment chemotherapy effectiveness by altering cancer cell differentiation and the epithelial-mesenchymal transition status, consequently extending survival in a mouse model of PDAC. This evidence concerns the gene LIF and neoplasm.